Skip to main content

Table 5 Utility weights by GOLD state and type of exacerbation

From: Cost-effectiveness of tiotropium versus usual care and glycopyrronium in the treatment of chronic obstructive pulmonary disease in Sweden

 

GOLD II

GOLD III

GOLD IV

No exacerbation

0.73

0.74

0.52

Non-severe exacerbation

0.72

0.73

0.51

Severe exacerbation

0.69

0.70

0.49

  1. Source: baseline utility weights (no exacerbation) [35], annual utility decrements [33]